Infectious Diseases in the Critically Ill Patients

Yost, Raymond

doi:10.1177/0897190010388906

Cited by 34 publications

(24 citation statements)

References 52 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. aureus is one of the main causes of bloodstream infections (3,4). Rapid identification of positive blood cultures is a prerequisite for timely targeted treatment of patients with sepsis (5-7).…”

mentioning

confidence: 99%

Evaluation of the BD Max StaphSR Assay for Rapid Identification of Staphylococcus aureus and Methicillin-Resistant S. aureus in Positive Blood Culture Broths

et al. 2015

View full text Add to dashboard Cite

bWe evaluated the performance of the BD Max StaphSR assay for the direct detection of Staphylococcus aureus from blood culture medium. In a two-center trial, 155 blood cultures from the BD Bactec FX system and 212 from the bioMérieux BacT/Alert system were tested; 170 bottles yielded S. aureus, and all were identified correctly by the BD Max StaphSR assay. The assay required approximately 2.5 h, thus allowing rapid identification of blood cultures flagged positive. The BD Max StaphSR assay (BD, Quebec, Canada) is a fully automated, qualitative, in vitro diagnostic test for the direct detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in patients at risk for nasal colonization. The test uses real-time PCR for the amplification of three DNA targets, i.e., SCCmec right-extremity junction (MREJ), thermostable nuclease (nuc), and methicillin resistance (mecA and mecC). Positivity for MREJ and mecA/mecC is required for the result "MRSA," and detection of nuc or MREJ without mecA/mecC is interpreted as "positive for S. aureus." The BD Max StaphSR assay was shown to have excellent sensitivity (96.4%) and specificity (93.6%), compared to combined direct and enriched cultures, for detection of S. aureus from anterior nares samples (1). In this study, we tested the performance of the StaphSR assay with a different sample type, namely, positive blood culture medium with Gram-positive cocci in clusters.Bloodstream infections often result in the need for intensive care and are associated with high mortality rates and large economic burdens (2). S. aureus is one of the main causes of bloodstream infections (3, 4). Rapid identification of positive blood cultures is a prerequisite for timely targeted treatment of patients with sepsis (5-7). Quick differentiation of S. aureus from coagulase-negative Staphylococcus (CoNS) can reduce the costs of patient care and decrease hospitalization times (8). The use of molecular assays for direct detection of S. aureus in blood culture bottles has been shown to allow rapid diagnosis of S. aureus septicemia, which might improve patient treatment (6, 9, 10). The recently introduced BD Max system allows fully automated realtime PCR, but the currently available BD Max StaphSR assay is CE marked and FDA cleared only for use with nasal swabs (11).In a first stage, we tested the use of the StaphSR assay with blood culture bottles (Bactec Plus Aerobic/F or Bactec Plus Anaerobic/F) that had been artificially inoculated with 1,000 CFU of MRSA, methicillin-susceptible S. aureus (MSSA), or methicillinresistant coagulase-negative Staphylococcus (MR-CoNS). After bottles were flagged positive, aliquots from those bottles were tested by inoculating the sample buffer tube (SBT) of the assay.The blood culture bottles were tested again after an additional 18 to 24 h of incubation, to mimic delayed analysis and to ensure that high DNA levels did not result in competition with any of the PCR target amplifications. We tested three volumes, i.e., 15, 50, and 100 l. All spiked blood cultu...

show abstract

mentioning

confidence: 99%

Evaluation of the BD Max StaphSR Assay for Rapid Identification of Staphylococcus aureus and Methicillin-Resistant S. aureus in Positive Blood Culture Broths

et al. 2015

View full text Add to dashboard Cite

show abstract

“…11 A meta-analysis found that the average attributable mortality to VAP is 32.5% in the ICU, 12 supported by another study 13 that found 33%. VAP increases the ICU and hospital length of stay, as well as the time the patient requires ventilatory support.…”

Section: Introductionmentioning

confidence: 92%

Prevention of ventilator-associated pneumonia

Oliveira

Zagalo

Cavaco‐Silva

2014

Revista Portuguesa de Pneumologia (English Edition)

View full text Add to dashboard Cite

“…Critically ill patients are at a higher risk for serious infections caused by multi-drug resistant organisms (MDROs). Particularly in the intensive care unit (ICU), nosocomial infections lead to increased length of stay, greater morbidity and mortality rates, and need for post-hospitalization care [4]. Many factors contribute to the higher risks in the ICU including invasive devices, surgical or traumatic wounds, disruption of skin barriers and mucosa, and alterations in adaptive immune responses [4].…”

Section: Introductionmentioning

confidence: 99%

“…Particularly in the intensive care unit (ICU), nosocomial infections lead to increased length of stay, greater morbidity and mortality rates, and need for post-hospitalization care [4]. Many factors contribute to the higher risks in the ICU including invasive devices, surgical or traumatic wounds, disruption of skin barriers and mucosa, and alterations in adaptive immune responses [4]. Other risk factors include immunosuppression, longer hospital stay, multiple chronic conditions, recent invasive procedures, previous antibiotic use within 90 days, and even receiving care in the critical care units [1].…”

Section: Introductionmentioning

confidence: 99%